Intraoperative 5-HT3 receptor antagonists decrease the prevalence of postoperative delirium in older adults undergoing hip fracture surgery: a single-center retrospective study
Purpose Postoperative delirium (POD) occurs commonly in older adults, resulting in unfavorable outcomes. Several recent clinical studies have suggested that 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonists can treat and prevent POD. In this retrospective study, the association between 5-HT 3 rec...
Gespeichert in:
Veröffentlicht in: | Journal of anesthesia 2023-06, Vol.37 (3), p.379-386 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
Postoperative delirium (POD) occurs commonly in older adults, resulting in unfavorable outcomes. Several recent clinical studies have suggested that 5-hydroxytryptamine 3 (5-HT
3
) receptor antagonists can treat and prevent POD. In this retrospective study, the association between 5-HT
3
receptor antagonists and POD was investigated in older adults who underwent hip fracture surgery.
Methods
The electronic medical records of older adults aged ≥ 65 years who underwent hip fracture surgery between January 2011 and June 2018 were reviewed retrospectively. Multivariable logistic regression analysis was used to investigate the association between 5-HT
3
receptor antagonists and the occurrence of POD. In addition to the incidence of POD, anesthesia-, surgery-, and patient-related factors related to POD were evaluated.
Results
Of the 1025 patients included, 813 (79.3%) were administered 5-HT
3
receptor antagonists intraoperatively; 471 (45.9%) were administered ramosetron, and 342 (33.4%) were administered palonosetron. POD was identified in 242 patients (23.6%). Ramosetron and palonosetron reduced the POD incidence by 53% (odds ratio [OR] 0.47; 95% confidence interval [CI] 0.32‒0.71;
P
|
---|---|
ISSN: | 0913-8668 1438-8359 |
DOI: | 10.1007/s00540-023-03169-5 |